600276.SHG Jiangsu Hengrui Medicine Co Ltd
- Market cap
- CNY 333B
- P/E
- 37.5x
- P/B
- 4.90x
- ROE
- 13.8%
- Dividend yield
- 0.38%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 600276.SHG undervalued?
Graham number600276.SHG trades 185.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jiangsu Hengrui Medicine Co Ltd fundamental analysis
No fundamental analysis for Jiangsu Hengrui Medicine Co Ltd yet.
Jiangsu Hengrui Medicine Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is …
Full company profileJiangsu Hengrui Medicine Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jiangsu Hengrui Medicine Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 11.1B | 13.8B | 17.4B | 23.3B | 27.7B | 25.9B | 21.3B | 22.8B | 28.0B | 31.4B | 32.5B |
| Gross Profit | 9.66B | 12.0B | 15.1B | 20.4B | 24.4B | 22.1B | 17.8B | 19.3B | 24.1B | 26.7B | 28.2B |
| Operating Income | 3.02B | 3.81B | 4.60B | 6.15B | 7.01B | 4.66B | 4.11B | 4.91B | 7.49B | 8.02B | 9.58B |
| EBITDA | 3.10B | 3.89B | 4.44B | 6.12B | 6.72B | 4.26B | 3.60B | 4.84B | 7.19B | 8.96B | 10.3B |
| Net Income | 2.59B | 3.22B | 4.07B | 5.33B | 6.33B | 4.53B | 3.91B | 4.30B | 6.34B | 7.71B | 9.23B |
| EPS | 0.41 | 0.50 | 0.63 | 0.84 | 1.00 | 0.71 | 0.61 | 0.68 | 1.00 | 1.18 | 1.39 |
| Balance Sheet | |||||||||||
| Total Assets | 14.3B | 18.0B | 22.4B | 27.6B | 34.7B | 39.3B | 42.4B | 43.8B | 50.1B | 69.9B | 76.7B |
| Total Liabilities | 1.46B | 2.10B | 2.56B | 2.62B | 3.94B | 3.69B | 3.94B | 2.75B | 4.05B | 7.69B | 9.38B |
| Shareholders' Equity | 12.4B | 15.4B | 19.7B | 24.8B | 30.5B | 35.0B | 37.8B | 40.5B | 45.5B | 61.3B | 66.8B |
| Cash & Short-term Investments | 4.91B | 4.27B | 3.89B | 13.6B | 16.4B | 18.7B | 17.9B | 20.8B | 25.1B | 41.1B | 43.4B |
| Total Debt | 43.4M | 528M | 655M | 420M | 1.60B | 152M | 1.36B | 75.2M | 69.0M | 938M | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.59B | 2.55B | 2.77B | 3.82B | 3.43B | 4.22B | 1.27B | 7.64B | 7.42B | 11.3B | - |
| Capital Expenditure | 1.11B | 380M | 529M | 561M | 554M | 1.66B | 1.99B | 1.48B | 1.97B | 2.96B | 3.56B |
| Free Cash Flow | 1.48B | 2.17B | 2.25B | 3.26B | 2.88B | 2.55B | -727M | 6.16B | 5.45B | 8.32B | 6.90B |
| Ratios | |||||||||||
| ROE | 20.9% | 20.9% | 20.6% | 21.5% | 20.7% | 12.9% | 10.3% | 10.6% | 13.9% | 12.6% | 13.8% |
| ROA | 18.1% | 17.8% | 18.2% | 19.3% | 18.2% | 11.5% | 9.2% | 9.8% | 12.6% | 11.0% | 12.0% |
| Net Profit Margin | 23.3% | 23.2% | 23.3% | 22.9% | 22.8% | 17.5% | 18.4% | 18.9% | 22.6% | 24.5% | 28.4% |
| Debt to Equity | 0.00x | 0.03x | 0.03x | 0.02x | 0.05x | 0.00x | 0.04x | 0.00x | 0.00x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jiangsu Hengrui Medicine Co Ltd dividends
- Dividend yield
- 0.38%
- Forward dividend
- 0.20 CNY
- Payout ratio
- 16.5%
- Ex-dividend date
- May 27, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 1.27B | 0.20 | 16.5% |
| 2024 | CNY 1.27B | 0.20 | 20.1% |
| 2023 | CNY 1.02B | 0.16 | 23.7% |
| 2022 | CNY 1.01B | 0.16 | 26.0% |
| 2021 | CNY 1.07B | 0.17 | 23.5% |
| 2020 | CNY 1.02B | 0.16 | 16.1% |
| 2019 | CNY 811M | 0.13 | 15.2% |
| 2018 | CNY 368M | 0.06 | 9.1% |
| 2017 | CNY 317M | 0.05 | 9.9% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.2:1 on Jun 10, 2021.
Who owns Jiangsu Hengrui Medicine Co Ltd
- Insiders 46.55%
- Institutions 11.65%
- Public & others 41.80%
- Shares outstanding 6.38B
- Free float 3.73B
Jiangsu Hengrui Medicine Co Ltd company profile
- Company name
- Jiangsu Hengrui Medicine Co Ltd
- Ticker
- 600276.SHG
- ISIN
- CNE0000014W7
- Exchange
- Shanghai Stock Exchange
- Listed since
- Sep 7, 2000
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 20,602
- Fiscal year end
- December
- Address
- No. 38, Huanghe Road, Lianyungang, China, 222047
- Phone
- 86 40 0828 3900
- Website
- hengrui.com
About Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. The company develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.
Jiangsu Hengrui Medicine Co Ltd management
10- Mr. Piao Yang SunExecutive Chairman of the Board · born 1958
- Ms. Ji FengGM, President, COO & Executive Director · born 1971
- Mr. Hong Bin DaiExecutive Deputy Chairman of the Board · born 1976
- Mr. Jie Ping SunSenior VP & Executive Director · born 1970
- Dr. Lian Shan Zhang Ph.D.Executive VP & Executive Director · born 1962
- Dr. Ningjun Jiang M.D., Ph.D.Executive VP, Chief Strategy Officer & Executive Director · born 1961
- Mr. Guoxin ZhuSenior Vice President
- Mr. Kin Chun LauChief Financial Officer · born 1979
- Jia Gang WuAccounting Supervisor
- Ms. Wing Han Leung C.P.A., FCCA, FCIS, FCS, FICSCompany Secretary